Moreover, we identified and validated S100A15, DOK2, TLR7, IL2RG, CRISP3, and TOP1MT as candidate biomarkers, which may provide an important mechanistic understanding of immune response regulation in patients with advanced stage NSCLC receiving first line combination chemotherapy. This evidence concerns the gene DOK2 and non-small cell lung carcinoma.